title: Recombinant activated factor VII for intractable bleeding post splenectomy in a patient with myeloproliferative disorder.
abstract: Recombinant activated factor VII has been Food and Drug Administration approved to treat hemorrhages in hemophiliac patients with inhibitors and in acquired hemophilia patients. Recombinant activated factor VII use has also been considered for the management of uncontrolled bleeding in a number of congenital and acquired hemostatic abnormalities. The myeloproliferative disorders are a group of clonal hematologic diseases where, frequently, abnormal platelet function is considered a hallmark. This is the first case report addressing the clinical benefit of off-label use of recombinant activated factor VII in an attempt to control intractable bleeding in a patient with a myeloproliferative disorder after splenectomy.
authors.affiliation: Division of Hematology/Oncology, American University of Beirut Medical Center, Beirut, Lebanon.
authors.forename: Abdul Rahman D
authors.initials: AR
authors.lastname: El Kinge
authors.forename: Rami A
authors.initials: RA
authors.lastname: Mahfouz
authors.forename: Ali I
authors.initials: AI
authors.lastname: Shamseddine
authors.forename: Ali T
authors.initials: AT
authors.lastname: Taher
mesh_terms: D001779:Blood Coagulation Factors / Q000627:therapeutic use*; D001791:Blood Platelet Disorders / Q000188:drug therapy*; D015942:Factor VIIa / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D008875:Middle Aged; D009196:Myeloproliferative Disorders / Q000150:complications*; D019106:Postoperative Hemorrhage / Q000188:drug therapy*; D013156:Splenectomy / Q000009:adverse effects
chemical_list: D001779:Blood Coagulation Factors; D015942:Factor VIIa